Premium
A phase 2 trial of whole‐brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
Author(s) -
Cassier Philippe A.,
RayCoquard Isabelle,
Sunyach MariePierre,
Lancry Laurence,
Guastalla JeanPaul,
Ferlay Céline,
Gomez Frédéric,
Curé Hervé,
Lortholary Alain,
Claude Line,
Blay JeanYves,
Bachelot Thomas
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23858
Subject(s) - medicine , vinorelbine , tolerability , chemotherapy , radiation therapy , breast cancer , oncology , brain metastasis , metastatic breast cancer , cancer , cisplatin , surgery , metastasis , adverse effect
BACKGROUND A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer. METHODS Twenty‐five patients with untreated brain metastases from breast cancer were treated with cisplatin (at a dose of 20 mg/m 2 /day, Days 1‐5) and vinorelbine (6‐mg/m 2 bolus on Day 1 and 6 mg/m 2 /day continuous infusion on Days 1‐5) chemotherapy combined with concurrent 30‐gray fractionated external‐beam radiotherapy. Chemotherapy was given at 3‐week intervals for a total of 4 cycles. Primary endpoint was the rate of radiologic response of brain metastases. RESULTS Complete response in the brain was observed in 3 patients, and partial response was noted in 16 patients, yielding a 76% response rate in the brain. The overall systemic response rate was 44%. Progression‐free and overall survival were 3.7 months and 6.5 months, respectively. Overall toxicity was acceptable; nonhematologic grade 3‐4 events were noted in 5 (20%) patients, and there were no toxic deaths. CONCLUSIONS Concurrent chemoradiation with cisplatin and vinorelbine for brain metastases from breast cancer appears to be active and well tolerated. Cancer 2008. © 2008 American Cancer Society.